Application of central small molecular protein DPP3 in preparation of antihypertensive drugs

According to the application of the central small molecule protein DPP3 in preparation of the antihypertensive drugs, the research shows that the expression level of the DPP3 in primary hypertension rat (SHR) RVLM is remarkably increased, and the sympathetic output blood pressure and blood pressure of WKY rats under consciousness and anesthesia are increased through overexpression of the DPP3 in the RVLM. When the expression of DPP3 in the RVLM is interfered in a hypertension state, sympathetic output can be inhibited, and blood pressure can be reduced. In addition, the DPP3 over-expressed in the RVLM of the WKY rat can degrade Ang-(1-7) to generate Ang-(5-7), and participates in blood pressure rise. By researching the effect of DPP3 in RVLM in regulating the production of angiotensin 5-7 in hypertension, a feasible theoretical basis and method are provided for treating hypertension by targeting central small molecular protein DPP3, so that the problems of poor patient compliance, high drug treatment cost and